August 2025 Product News: FDA Approvals Drive Progress in Shingles, Diabetes, and Heart Health

Prescription Product Milestones

August 2025 marks a period of significant advancements in the pharmaceutical landscape, with the FDA granting key approvals that promise to improve patient care and access to essential medications.

GSK’s Shingrix: A New Era of Convenience

GSK has received FDA approval for a new prefilled syringe presentation of its highly effective shingles vaccine, Shingrix. This development simplifies the vaccination process by eliminating the need for healthcare providers to manually reconstitute separate vials before administration. Shingrix is a nonlive vaccine that works by combining the glycoprotein E antigen with an adjuvant system, AS01B, which is designed to enhance the immune response, particularly in older adults. It is approved for the prevention of shingles in adults aged 50 and older, as well as for immunocompromised or immunosuppressed individuals aged 18 and older. This new, ready-to-use formulation aims to streamline clinical workflow and potentially increase vaccination rates.

Biocon’s Kirsty: Paving the Way for Interchangeable Insulin

In a groundbreaking move for diabetes care, the FDA has approved insulin aspart-xjhz (Kirsty) from Biocon, making it the first interchangeable biosimilar to insulin aspart (NovoLog). This designation is crucial because it allows pharmacists to substitute Kirsty for the reference product without a new prescription, based on state laws. This is expected to significantly improve patient access to a more affordable rapid-acting insulin therapy. Kirsty is indicated to enhance glycemic control in both adult and pediatric patients with diabetes. It will be available in two formulations to suit a variety of patient needs: a 3-mL single-patient-use prefilled pen and a 10-mL multiple-dose vial. The vial formulation offers additional flexibility, as it is also approved for use via an insulin pump or intravenous infusion.

Over-the-Counter and Generic Advancements

Olly’s Big 10 Probiotic: A Shelf-Stable Solution for Gut Health

Olly is expanding its wellness offerings with the launch of its new over-the-counter supplement, Big 10 Probiotic. This product is a blend of several beneficial bacterial strains, including Lactobacillus plantarum, two other Lactobacillus strains, and Bifidobacterium animalis. Designed with patient convenience in mind, the formula is shelf-stable and does not require refrigeration. The product was developed using a data-first approach, with ingredients selected based on evidence supporting their roles in promoting digestive balance, boosting immune function, enhancing gut biodiversity, and improving stress resilience.

Taro Pharmaceuticals’ Rivaroxaban: The First Generic for Cardiovascular Patients

In a move that will increase affordability and access for patients at high cardiovascular risk, the FDA has approved the first generic version of rivaroxaban 2.5 mg from Taro Pharmaceuticals. This low-dose oral anticoagulant is indicated for use in adults with coronary artery disease and peripheral artery disease to reduce the risk of major cardiovascular and thrombotic events. The approval was supported by data from the landmark COMPASS and VOYAGER PAD clinical trials, which demonstrated a statistically significant reduction in cardiovascular events when rivaroxaban 2.5 mg was added to aspirin therapy compared to aspirin alone. The introduction of this generic will provide a more cost-effective option for a proven, guideline-supported treatment, which could lead to improved medication adherence and better long-term health outcomes for a vulnerable patient population.